Many health and wellness stocks have faced challenges in recent years as GLP-1 weight-loss drugs like Ozempic and Wegovy upend the traditional diet market. Companies that once dominated the space ...

It comes as the weight loss company had been struggling under $1.6billion (£1.2billion) of debt after losing business to revolutionary weight loss drugs such as Ozempic and Wegovy.